Article
type: Class

Document
type: Class

Anualidad
type: Class

Academic Article
type: Class

Information Content Entity
type: Class

2020
type: Class

Continuant
type: Class

Entity
type: Class

Generically Dependent Continuant
type: Class

RDF description of Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up - http://research.umh.es/vivo/pub/articulo/218558
type: Document
rights: termsOfUse
date: 2026-08-29T01:57:17
publisher: Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up
type: Entity
page start: 1
has publication venue: JOURNAL OF AUTOIMMUNITY
type: Article
type: Information Content Entity
type: Academic Article
type: Continuant
date time value: 218558 pubdate
most specific type: Academic Article
type: Generically Dependent Continuant
most specific type: 2020
type: Anualidad
related by: Autor:161153-Artículo:218558
page end: 2
type: Thing
type: Document
ARG_2000028: 218558 vcard
included: Producción Vegetal y Microbiología 2020
type: 2020

JOURNAL OF AUTOIMMUNITY
type: Thing
publication venue for: Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up
type: Entity
type: Collection
type: Generically Dependent Continuant
type: Information Content Entity
type: Journal
type: Periodical
type: Continuant

Autor:161153-Artículo:218558
type: Relationship
type: BFO_0000020
type: Entity
type: Thing
type: Authorship
type: Continuant
relates: Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up

Producción Vegetal y Microbiología 2020
type: Anualidad
type: 2020
type: DepartmentReport
type: Thing
type: ResearchReport
includes: Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up